Mark O’Neill

Mark O’Neill FCA

Chief Financial Officer

Mark heads up the Finance function in Afimmune. Mark has a wealth of experience in bringing products to market and company financing. Prior to joining Afimmune, he held a number of senior financial and operational positions in organisations ranging from start-up enterprises to large global established companies.

In addition to being Chief Financial Officer of Afimmune, Mark is Chief Executive Officer of related company, DS Biopharma. Mark represents DS Biopharma as a Director on the Board of Nuvothera Inc. a commercial dermatology company based in the United States. Mark is co-founder of HAON Life Sciences, developing a novel cell therapy for newborn brain injury. Mark is also Chairman of the Human Dignity Foundation Audit and Investment Committee, a private charitable foundation.

Mark is a fellow of the Institute of Chartered Accountants (Ireland), having qualified in Deloitte. A Commerce graduate from University College Dublin, Mark also holds a Masters of Accounting from the Smurfit School of Business and a Diploma in Corporate Finance from the Institute of Chartered Accountants.